Jensen A D, Guarnieri F, Rasmussen S G, Asmar F, Ballesteros J A, Gether U
Division of Cellular and Molecular Physiology, Department of Medical Physiology, The Panum Institute, Copenhagen University, DK-2200 Copenhagen N, Denmark.
J Biol Chem. 2001 Mar 23;276(12):9279-90. doi: 10.1074/jbc.M004871200. Epub 2000 Dec 15.
The environmentally sensitive, sulfhydryl-reactive, fluorescent probe N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ethylene-diamine (IANBD) was used as a molecular reporter of agonist-induced conformational changes in the beta(2) adrenergic receptor, a prototype hormone-activated G protein-coupled receptor. In the background of a mutant beta(2) adrenergic receptor, with a minimal number of endogenous cysteine residues, new cysteines were introduced in positions 269(6.31), 270(6.32), 271(6.33), and 272(6.34) at the cytoplasmic side of transmembrane segment (TM) 6. The resulting mutant receptors were fully functional and bound both agonists and antagonist with high affinities also upon IANBD labeling. Fluorescence spectroscopy analysis of the purified and site-selectively IANBD-labeled mutants suggested that the covalently attached fluorophore was exposed to a less polar environment at all four positions upon agonist binding. Whereas evidence for only a minor change in the molecular environment was obtained for positions 269(6.31) and 270(6.32), the full agonist isoproterenol caused clear dose-dependent and reversible increases in fluorescence emission at positions 271(6.33) and 272(6.34). The data suggest that activation of G protein-coupled receptors, which are activated by "diffusible" ligands, involves a structural rearrangement corresponding to the cytoplasmic part of TM 6. The preferred conformations of the IANBD moiety attached to the inserted cysteines were predicted by employing a computational method that incorporated the complex hydrophobic/hydrophilic environment in which the cysteines reside. Based on these preferred conformations, it is suggested that the spectral changes reflect an agonist-promoted movement of the cytoplasmic part of TM 6 away from the receptor core and upwards toward the membrane bilayer.
对环境敏感的、巯基反应性荧光探针N,N'-二甲基-N-(碘乙酰基)-N'-(7-硝基苯并-2-恶唑-1,3-二氮杂环丁烷-4-基)乙二胺(IANBD)被用作β₂肾上腺素能受体激动剂诱导构象变化的分子报告物,β₂肾上腺素能受体是一种典型的激素激活型G蛋白偶联受体。在具有最少内源性半胱氨酸残基的突变型β₂肾上腺素能受体背景下,在跨膜片段(TM)6胞质侧的269(6.31)、270(6.32)、271(6.33)和272(6.34)位置引入了新的半胱氨酸。所得的突变型受体功能完全正常,并且在IANBD标记后也能以高亲和力结合激动剂和拮抗剂。对纯化的、位点选择性IANBD标记的突变体进行荧光光谱分析表明,在激动剂结合后,共价连接的荧光团在所有四个位置都暴露于极性较小的环境中。虽然在269(6.31)和270(6.32)位置仅获得了分子环境微小变化的证据,但完全激动剂异丙肾上腺素在271(6.33)和272(6.34)位置引起了荧光发射明显的剂量依赖性和可逆性增加。数据表明,由“可扩散”配体激活的G蛋白偶联受体的激活涉及与TM 6胞质部分相对应的结构重排。通过采用一种计算方法预测了连接到插入半胱氨酸上的IANBD部分的优选构象,该方法纳入了半胱氨酸所处的复杂疏水/亲水环境。基于这些优选构象,表明光谱变化反映了激动剂促进的TM 6胞质部分从受体核心移开并向上朝向膜双层的运动。